Equities Analysts Offer Predictions for VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Verve Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings of ($2.67) per share for the year. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share.

Other analysts have also issued research reports about the company. Royal Bank of Canada lowered their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group increased their price target on Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright decreased their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th.

Verve Therapeutics Trading Up 7.0 %

Shares of VERV opened at $6.57 on Wednesday. Verve Therapeutics has a 1-year low of $4.30 and a 1-year high of $19.34. The company has a 50-day moving average of $5.80 and a 200 day moving average of $5.77.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The business had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business’s revenue was up 120.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.72) earnings per share.

Institutional Trading of Verve Therapeutics

A number of hedge funds have recently bought and sold shares of VERV. GAMMA Investing LLC raised its position in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after acquiring an additional 3,964 shares in the last quarter. Creative Planning bought a new position in Verve Therapeutics in the third quarter worth about $50,000. PFG Investments LLC purchased a new stake in shares of Verve Therapeutics during the third quarter valued at about $53,000. Erste Asset Management GmbH purchased a new stake in shares of Verve Therapeutics during the third quarter valued at about $56,000. Finally, Impact Partnership Wealth LLC bought a new stake in shares of Verve Therapeutics in the 4th quarter valued at about $70,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.